Nektar Therapeutics reported $6.95M in Interest Expense on Debt for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Expense On Debt Change
ALKERMES ALKS:US USD 3.55M 1.18M
Amgen AMGN:US USD 415M 47M
Baxter International BAX:US USD 109M 16M
Biocryst Pharmaceuticals BCRX:US USD 24.78M 753K
Biogen BIIB:US USD 59.9M 5.9M
Bristol Myers Squibb BMY:US USD 294M 5M
Esperion Therapeutics ESPR:US USD 14.15M 113K
Gilead Sciences GILD:US USD 227M 2M
Halozyme Therapeutics HALO:US USD 7.51M 4.41M
Immunogen IMGN:US USD 867K 211K
IONIS PHARMACEUT IONS:US USD 2.14M 9K
Ironwood Pharmaceuticals IRWD:US USD 1.52M 683K
Karyopharm Therapeutics KPTI:US USD 6.11M 199K
Nektar Therapeutics NKTR:US USD 6.95M 275K
Neurocrine Biosciences NBIX:US USD 1.2M 1000K
Novartis NOVN:VX USD 215M 13M
Pfizer PFE:US USD 313M 2M
Roche Holding ROG:VX 256M 90M
Sarepta Therapeutics SRPT:US USD 14.74M 1.29M
Teva Pharmaceutical TEVA:IT USD 230M 5M
YTE INCY:US USD 641K 37K